Can A Multivariate Model for Survival Estimation in Skeletal Metastases (PATHFx) Be Externally Validated Using Japanese Patients?
Koichi Ogura(National Cancer Center), Jonathan A. Forsberg(Memorial Sloan Kettering Cancer Center), Tatsuya Takagi(Juntendo University), Yusuke Shinoda(The University of Tokyo), Hirotaka Kawano(University of Tokyo Hospital), Tabu Gokita, Rikard Wedin(Karolinska University Hospital), Keisuke Ae(The Cancer Institute Hospital), Akira Kawai(NTT (Japan))
Cited by 38
Related Papers
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2021|558
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2021|453
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264